Who are MDD diagnosis and Fluoxetine treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lexapro, Prozac, Sertraline HCl, SSRI (SEROPLEX ou ZOLOFT), oral escitalopram, SSRI antidepressants.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mdd-diagnosis-and-fluoxetine-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

MDD diagnosis and Fluoxetine treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MDD diagnosis and Fluoxetine treatment (MDD diagnosis and Fluoxetine treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Serotonin Reuptake Inhibitor (SSRI). Area: Neuroscience.

marketed Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin Transporter (SERT) Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

MDD diagnosis and Fluoxetine treatment (MDD diagnosis and Fluoxetine treatment) — University of Pennsylvania.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MDD diagnosis and Fluoxetine treatment TARGET	MDD diagnosis and Fluoxetine treatment	University of Pennsylvania	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin Transporter (SERT)
Lexapro	escitalopram	Generic (originally Lundbeck/Forest)	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter	2002-08-14
Prozac	fluoxetine	Eli Lilly and Company	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
Sertraline HCl	Sertraline HCl	Tri-Service General Hospital	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
SSRI (SEROPLEX ou ZOLOFT)	SSRI (SEROPLEX ou ZOLOFT)	Centre Hospitalier Universitaire Dijon	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
oral escitalopram	oral escitalopram	NYU Langone Health	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
SSRI antidepressants	SSRI antidepressants	Nanjing Medical University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Serotonin Reuptake Inhibitor (SSRI) class)

Eli Lilly and Company · 1 drug in this class
Generic (originally Lundbeck/Forest) · 1 drug in this class
Pfizer Inc. · 1 drug in this class
University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MDD diagnosis and Fluoxetine treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/mdd-diagnosis-and-fluoxetine-treatment. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab